Brokerages Set Sutro Biopharma, Inc. (NASDAQ:STRO) Price Target at $12.13

Sutro Biopharma, Inc. (NASDAQ:STROGet Free Report) has been given a consensus rating of “Buy” by the eight research firms that are covering the firm, MarketBeat.com reports. Eight equities research analysts have rated the stock with a buy rating. The average 1-year target price among analysts that have issued a report on the stock in the last year is $12.13.

STRO has been the topic of several analyst reports. HC Wainwright restated a “buy” rating and set a $12.00 price target on shares of Sutro Biopharma in a research report on Friday. JMP Securities restated a “market outperform” rating and issued a $17.00 price target on shares of Sutro Biopharma in a research note on Monday, September 16th. Piper Sandler reaffirmed an “overweight” rating and issued a $11.00 price target on shares of Sutro Biopharma in a report on Friday. Finally, Truist Financial dropped their price objective on Sutro Biopharma from $18.00 to $15.00 and set a “buy” rating on the stock in a report on Friday, August 16th.

View Our Latest Analysis on Sutro Biopharma

Hedge Funds Weigh In On Sutro Biopharma

Several hedge funds and other institutional investors have recently made changes to their positions in STRO. Opaleye Management Inc. acquired a new position in Sutro Biopharma in the 4th quarter valued at $1,293,000. Susquehanna Fundamental Investments LLC purchased a new position in shares of Sutro Biopharma in the first quarter worth about $714,000. Acadian Asset Management LLC boosted its position in Sutro Biopharma by 30.5% during the first quarter. Acadian Asset Management LLC now owns 1,204,253 shares of the company’s stock worth $6,803,000 after acquiring an additional 281,224 shares during the last quarter. Vanguard Group Inc. grew its stake in Sutro Biopharma by 4.6% during the 1st quarter. Vanguard Group Inc. now owns 3,022,790 shares of the company’s stock valued at $17,079,000 after acquiring an additional 132,790 shares in the last quarter. Finally, Renaissance Technologies LLC raised its holdings in Sutro Biopharma by 48.1% in the 2nd quarter. Renaissance Technologies LLC now owns 719,497 shares of the company’s stock valued at $2,108,000 after acquiring an additional 233,700 shares during the last quarter. Hedge funds and other institutional investors own 96.99% of the company’s stock.

Sutro Biopharma Stock Up 14.5 %

Sutro Biopharma stock opened at $3.79 on Wednesday. The business’s 50-day moving average price is $3.94 and its 200 day moving average price is $3.93. The firm has a market cap of $310.00 million, a price-to-earnings ratio of -2.02 and a beta of 1.17. Sutro Biopharma has a 52 week low of $2.01 and a 52 week high of $6.13.

Sutro Biopharma (NASDAQ:STROGet Free Report) last issued its quarterly earnings data on Tuesday, August 13th. The company reported ($0.59) EPS for the quarter, topping analysts’ consensus estimates of ($0.79) by $0.20. The business had revenue of $25.71 million for the quarter, compared to analysts’ expectations of $26.28 million. Sutro Biopharma had a negative net margin of 73.48% and a negative return on equity of 102.06%. Equities analysts expect that Sutro Biopharma will post -2.96 EPS for the current year.

About Sutro Biopharma

(Get Free Report

Sutro Biopharma, Inc operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer.

Further Reading

Analyst Recommendations for Sutro Biopharma (NASDAQ:STRO)

Receive News & Ratings for Sutro Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sutro Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.